Merck has responded to an FDA “approvable” letter for Arcoxia (etoricoxib), an investigational selective Cox-2 inhibitor, with results of the MEDAL program. The company is hoping Arcoxia can take the place of Vioxx.
From the January 01, 2007 Issue of MM+M - Medical Marketing and Media